Chemours’ Leadership Shakeup and Disclosure Delays Might Change The Case For Investing In Chemours (CC)

Simply Wall St.

Sep 22, 2025

Earlier this month, Kahn Swick & Foti, LLC initiated an investigation into The Chemours Company following the delayed filing of its 2023 annual report, which the company attributed to potential ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2569736510"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569736510\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569736510?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice2-main-header/1585186835382","is_english":true,"pubTime":"2025-09-22 20:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569736510","market":"us","top_or_hot":-1,"title":"Chemours’ Leadership Shakeup and Disclosure Delays Might Change The Case For Investing In Chemours (CC)","media":"Simply Wall St.","content":"<div>\n<p>Earlier this month, Kahn Swick & Foti, LLC initiated an investigation into The Chemours Company following the delayed filing of its 2023 annual report, which the company attributed to potential ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/chemours-leadership-shakeup-and-disclosure-delays-might-chan\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chemours’ Leadership Shakeup and Disclosure Delays Might Change The Case For Investing In Chemours (CC)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChemours’ Leadership Shakeup and Disclosure Delays Might Change The Case For Investing In Chemours (CC)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-22 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/chemours-leadership-shakeup-and-disclosure-delays-might-chan><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Earlier this month, Kahn Swick & Foti, LLC initiated an investigation into The Chemours Company following the delayed filing of its 2023 annual report, which the company attributed to potential ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/chemours-leadership-shakeup-and-disclosure-delays-might-chan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CC","symbol_name":"Chemours Company","start_time":0,"source_url":"https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/chemours-leadership-shakeup-and-disclosure-delays-might-chan","article_id":"2569736510","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice2-main-header/1585186835382"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-cc/chemours/news/chemours-leadership-shakeup-and-disclosure-delays-might-chan","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2569736510","pubTimestamp":1758544188,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Earlier this month, Kahn Swick & Foti, LLC initiated an investigation into The Chemours Company following the delayed filing of its 2023 annual report, which the company attributed to potential material weaknesses in its internal controls; as part of its response, Chemours placed its President/CEO, Senior VP/CFO, and Controller on administrative leave while an internal review is conducted under Audit Committee oversight.\nThis series of developments raises fresh questions about senior...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CC":"Chemours Company","BK4098":"多种化学制品"},"translate_title":"科慕领导层变动和披露延迟可能会改变投资科慕(CC)的理由","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CC":1.5},"content_text":"Earlier this month, Kahn Swick & Foti, LLC initiated an investigation into The Chemours Company following the delayed filing of its 2023 annual report, which the company attributed to potential material weaknesses in its internal controls; as part of its response, Chemours placed its President/CEO, Senior VP/CFO, and Controller on administrative leave while an internal review is conducted under Audit Committee oversight. This series of developments raises fresh questions about senior management oversight and transparency in the handling of Chemours’ financial reporting processes. We’ll examine how recent concerns over Chemours’ internal controls may alter the company’s investment narrative and perceived risk profile. Find companies with promising cash flow potential yet trading below their fair value.AdvertisementChemours Investment Narrative RecapTo own Chemours, investors need to believe in its ability to lead in specialty chemicals despite regulatory and legal headwinds, driven mainly by demand growth in advanced materials and low-GWP refrigerants. However, the recent investigation into delayed financial reporting and the administrative leave of key executives introduces significant uncertainty around internal controls, directly impacting short-term confidence and elevating governance-related risk as the central near-term concern. The biggest catalyst remains continued regulatory-driven adoption of Opteon refrigerants, but for now, the most important risk is internal oversight and transparency in financial processes. The most relevant recent announcement is the August 4, 2025 proposed $875 million settlement with New Jersey to resolve environmental claims linked to PFAS. This action is closely tied to Chemours’ exposure to legal and compliance risks and overlaps with the uncertainties surrounding the internal investigation, as both matters go to the heart of the company's long-term liability management and financial disclosure practices. By contrast, while investors often focus on growth catalysts like Opteon, the evolving risk around corporate oversight is one important factor you need to consider... Read the full narrative on Chemours (it's free!)Chemours' outlook anticipates $6.6 billion in revenue and $671.0 million in earnings by 2028. This scenario implies 3.9% annual revenue growth and a $1,083 million increase in earnings from -$412.0 million currently.Uncover how Chemours' forecasts yield a $15.44 fair value, a 9% downside to its current price.Exploring Other PerspectivesCC Community Fair Values as at Sep 2025 Five estimates from the Simply Wall St Community place Chemours’ fair value between US$11.55 and US$19.23 per share. While many are optimistic about future profit growth, recent questions over internal controls point to significant potential volatility beyond these benchmarks, reviewing a wide range of investor views is essential.Explore 5 other fair value estimates on Chemours - why the stock might be worth 32% less than the current price!Build Your Own Chemours NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Chemours research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Chemours research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemours' overall financial health at a glance.Curious About Other Options?Our top stock finds are flying under the radar-for now. Get in early:AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Outshine the giants: these 24 early-stage AI stocks could fund your retirement.We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}